AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12791621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 0 mg caffeine
Number of subjects: 12
Study 12791621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 1 mg nicotine and 50 mg caffeine
Number of subjects: 12
Study 12791621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 50 mg caffeine
Number of subjects: 12
Study 12791621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 1 mg nicotine and 100 mg caffeine
Number of subjects: 12
Study 12791621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 100 mg caffeine
Number of subjects: 12
Study 12791621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg nicotine and 0 mg caffeine)
Number of subjects: 12
Study 10669280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 80
Study 10669280 — intervention group
Group type: COMPARATOR
Intervention: Halothane 5%
Number of subjects: 80
Study 8839527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane temperature measurement
Number of subjects: 37
Study 8839527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 37
Study 1338387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 60 mg daily for 14 days
Number of subjects: 16
Study 1338387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1338387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 16
Study 31953727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypectomy with careful inspection during both insertion and withdrawal
Number of subjects: 1142
Study 31953727 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (polypectomy during withdrawal only)
Number of subjects: 1142
Study 31953727 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard colonoscopy)
Number of subjects: 1142
Study 29323617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with oncology care
Number of subjects: 350
Study 29323617 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 350
Study 27552934 — intervention group
Group type: EXPERIMENTAL
Intervention: Approval by the Medical Ethics Review Committee (METC)
Number of subjects: 2
Study 27552934 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of documents required for approval
Number of subjects: 2
Study 27552934 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs charged for approval procedures
Number of subjects: 2
Study 24148020 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with a converted pre-existing denture on the day of surgery.
Number of subjects: 42
Study 24148020 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of implants (control group) with soft-relined pre-existing denture.
Number of subjects: 42
Study 22475087 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnosis
Number of subjects: 220
Study 22475087 — intervention group
Group type: COMPARATOR
Intervention: Group relaxation
Number of subjects: 220
Study 20159816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1 (527 patients)
Number of subjects: 1053
Study 20159816 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/infusional fluorouracil (526 patients)
Number of subjects: 1053
Study 20159816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1
Number of subjects: 1053
Study 20159816 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/infusional fluorouracil
Number of subjects: 1053
Study 17621644 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily (titrated to a maximum of 120 mg daily)
Number of subjects: 177
Study 16449090 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV)
Number of subjects: 40
Study 16449090 — intervention group
Group type: COMPARATOR
Intervention: Methadone and LAAM
Number of subjects: 40
Study 12560163 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix25
Number of subjects: 151
Study 12560163 — intervention group
Group type: COMPARATOR
Intervention: Human insulin 30/70
Number of subjects: 151
Study 10767227 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation program including 3 months of breathing retraining and chest physiotherapy, 3 months of daily supervised exercise, and 6 months of weekly supervised breathing exercises
Number of subjects: 60
Study 10767227 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 9549298 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 40
Study 9549298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8350293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 46
Study 8350293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate lymphadenectomy
Number of subjects: 171
Study 3747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed lymphadenectomy
Number of subjects: 171
Study 3747613 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 171
Study 30071894 — intervention group
Group type: COMPARATOR
Intervention: Exclusion diets
Number of subjects: 30
Study 30071894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimuno® galactooligosaccharide (B‐GOS®) prebiotic intervention
Number of subjects: 30
Study 26885681 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with ginsenoside Rg3
Number of subjects: 228
Study 26885681 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 228
Study 24751462 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 160
Study 24751462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21751299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment acceptance
Number of subjects: 106
Study 21751299 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT participation
Number of subjects: 106
Study 20938953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral removal of proximal submandibular stones (IORS group)
Number of subjects: 44
Study 20938953 — intervention group
Group type: COMPARATOR
Intervention: Submandibular gland resection (SMGR group)
Number of subjects: 44
Study 19189603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 1.25‐8.75 mg per day
Number of subjects: 25
Study 16291415 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25-600 mg/d for 26 weeks)
Number of subjects: 205
Study 16291415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 12558761 — intervention group
Group type: EXPERIMENTAL
Intervention: Queckenstedt's maneuver in the supine position
Number of subjects: 25
Study 12558761 — intervention group
Group type: EXPERIMENTAL
Intervention: Queckenstedt's maneuver in the sitting position
Number of subjects: 25
Study 12558761 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain increase between supine and upright positions
Number of subjects: 25
Study 10511769 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 341
Study 10511769 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 341
Study 10511769 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 341
Study 7572704 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g ethanol
Number of subjects: 37
Study 7572704 — intervention group
Group type: COMPARATOR
Intervention: equienergetic fruit juice
Number of subjects: 37
Study 1938771 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (Alupent) metered dose inhaler
Number of subjects: 268
Study 1938771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 7006708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation with cyclophosphamide (CY) 60 mg/kg/day for 2 days, 1000 rad total body irradiation, and a marrow transplant from a genotypically identical normal twin.
Number of subjects: 34
Study 7006708 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy consisting of killed autologous leukemic cells and/or normal twin peripheral blood lymphocytes.
Number of subjects: 34
Study 7006708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but includes patients who did not receive additional chemotherapy before CY).
Number of subjects: 34
Study 30802897 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement interview
Number of subjects: 120
Study 30802897 — intervention group
Group type: COMPARATOR
Intervention: Control visit
Number of subjects: 120
Study 30802897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 120
Study 30802897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120
Study 28287818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over 3 months)
Number of subjects: 184
Study 28287818 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 184
Study 25802961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity wheelchair training (30%–40% heart rate reserve, twice a week, 30 mins per session for 16 weeks)
Number of subjects: 29
Study 23490326 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 188
Study 23490326 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate
Number of subjects: 188
Study 21434339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongnao Huoluo Acupuncture (THA) in Group A
Number of subjects: 397
Study 21434339 — intervention group
Group type: EXPERIMENTAL
Intervention: THA in Group D
Number of subjects: 397
Study 21434339 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with urokinase in Group B
Number of subjects: 397
Study 21434339 — intervention group
Group type: COMPARATOR
Intervention: Batroxobin in Group C
Number of subjects: 397
Study 21434339 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture in Group E
Number of subjects: 397
Study 21434339 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in Group F
Number of subjects: 397
Study 19174427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic strategies
Number of subjects: 0
Study 19174427 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic strategies
Number of subjects: 0
Study 17244100 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education and coaching session (20 minutes)
Number of subjects: 67
Study 17244100 — intervention group
Group type: COMPARATOR
Intervention: Standardized information on controlling pain (Control group)
Number of subjects: 67
Study 14623806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis (within 2 hours)
Number of subjects: 834
Study 14623806 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI (within 2 hours)
Number of subjects: 834
Study 14623806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis (>=2 hours)
Number of subjects: 834
Study 14623806 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI (>=2 hours)
Number of subjects: 834
Study 10808980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention course
Number of subjects: 338
Study 10808980 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-oriented general health course
Number of subjects: 338
Study 8828938 — intervention group
Group type: EXPERIMENTAL
Intervention: iodoxamide tromethamine (LT)
Number of subjects: 40
Study 8828938 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine (KT)
Number of subjects: 40
Study 1643920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 58
Study 1643920 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data, lung function, chest roentgenogram, and serologic parameters
Number of subjects: 58
Study 3887394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anti-lymphocyte globulin (ALG) combined with azathioprine and steroids for 8.7 +/- 2.25 days after transplantation, followed by cyclosporine and steroids.
Number of subjects: 0
Study 3887394 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and steroids only (control group).
Number of subjects: 0
Study 29338113 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg (97/103 mg)
Number of subjects: 376
Study 29338113 — intervention group
Group type: COMPARATOR
Intervention: olmesartan 20 mg
Number of subjects: 376
Study 27097799 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-intervention (n=29)
Number of subjects: 67
Study 27097799 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 67
Study 27097799 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline OPA
Number of subjects: 67
Study 27097799 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LTPA
Number of subjects: 67
Study 27097799 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA directly recorded
Number of subjects: 67
Study 27097799 — intervention group
Group type: EXPERIMENTAL
Intervention: LTPA directly recorded
Number of subjects: 67
Study 24341948 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg metronidazole tablet (Flagyl®)
Number of subjects: 13
Study 24341948 — intervention group
Group type: COMPARATOR
Intervention: 3 g of 15% metronidazole benzoate gel
Number of subjects: 13
Study 22172481 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training with inexpensive, self‐contained trainer boxes
Number of subjects: 20
Study 22172481 — intervention group
Group type: COMPARATOR
Intervention: Simulation center training using standard video trainers
Number of subjects: 20
Study 19913119 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (single infusion)
Number of subjects: 46
Study 19913119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride infusion)
Number of subjects: 46
Study 17656480 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + PAN dissection
Number of subjects: 260
Study 17656480 — intervention group
Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 260
Study 16257245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach flower remedies
Number of subjects: 40
Study 16257245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12677972 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 60
Study 10492054 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg
Number of subjects: 169
Study 10492054 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 40 mg
Number of subjects: 169
Study 10492054 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 169
Study 10492054 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine 45 mg
Number of subjects: 169
Study 10492054 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine 90 mg
Number of subjects: 169
Study 10492054 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 169
Study 8564100 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 micrograms in 4 ml saline)
Number of subjects: 7
Study 8564100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2119575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (treated for two days prior to surgery)
Number of subjects: 0
Study 2119575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (direct addition to vein segments in vitro)
Number of subjects: 0
Study 2119575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 2119575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (in the absence of arachidonic acid)
Number of subjects: 0
Study 6988176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone in an oily cream base
Number of subjects: 60
Study 6988176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone 17-butyrate cream
Number of subjects: 60
Study 6988176 — intervention group
Group type: COMPARATOR
Intervention: Oily cream base alone
Number of subjects: 60
Study 31829186 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (educational meeting, implementation team, workshops)
Number of subjects: 0
Study 31829186 — intervention group
Group type: COMPARATOR
Intervention: Single implementation strategy (educational meeting)
Number of subjects: 0
Study 31829186 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 0
Study 31829186 — intervention group
Group type: COMPARATOR
Intervention: Single implementation strategy
Number of subjects: 0
Study 28732523 — intervention group
Group type: EXPERIMENTAL
Intervention: Collabri model for collaborative care (CC)
Number of subjects: 480
Study 28732523 — intervention group
Group type: COMPARATOR
Intervention: Standard detection
Number of subjects: 480
Study 28732523 — intervention group
Group type: COMPARATOR
Intervention: Case finding (with the recommended screening tool Major Depression Inventory (MDI))
Number of subjects: 480
Study 26010755 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Choice decision aid
Number of subjects: 79
Study 26010755 — intervention group
Group type: COMPARATOR
Intervention: FRAX only and Usual Care
Number of subjects: 79
Study 24321466 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency/physical exam-indicated cerclage in twin pregnancies
Number of subjects: 43
Study 24321466 — intervention group
Group type: COMPARATOR
Intervention: Emergency/physical exam-indicated cerclage in singleton pregnancies
Number of subjects: 43
Study 22914509 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased authenticity of instructional formats (paper, DVD, standardized patient)
Number of subjects: 0
Study 22914509 — intervention group
Group type: COMPARATOR
Intervention: Paper case
Number of subjects: 0
Study 22914509 — intervention group
Group type: EXPERIMENTAL
Intervention: More authentic instructional formats
Number of subjects: 0
Study 19230029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutathione 1,400 mg administered three times a week for 4 weeks
Number of subjects: 21
Study 19230029 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a week for 4 weeks
Number of subjects: 21
Study 19230029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutathione 1,400 mg
Number of subjects: 21
Study 19230029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17302768 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support (DS) intervention with computerized physician order entry (CPOE) for transfusion orders
Number of subjects: 1752
Study 17302768 — intervention group
Group type: COMPARATOR
Intervention: Conventional education intervention
Number of subjects: 1752
Study 17302768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DS intervention)
Number of subjects: 1752
Study 17302768 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-recommended orders
Number of subjects: 1752
Study 15358690 — intervention group
Group type: EXPERIMENTAL
Intervention: bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d)
Number of subjects: 33
Study 15358690 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 11334206 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukodepletion and aprotinin
Number of subjects: 0
Study 11334206 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9739333 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN alpha 2a for 48 weeks (group I, n = 37)
Number of subjects: 76
Study 9739333 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU IFN alpha 2a for 48 weeks (group II, n = 39)
Number of subjects: 76
Study 9739333 — intervention group
Group type: COMPARATOR
Intervention: 9 MU IFN alpha 2a for 48 weeks (group III, n = 45)
Number of subjects: 76
Study 7525192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination antihypertensive therapy
Number of subjects: 0
Study 7525192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy
Number of subjects: 0
Study 7525192 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic with potassium-sparing diuretic, β-blocker, or ACE inhibitor
Number of subjects: 0
Study 7525192 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker with β-blocker or ACE inhibitor
Number of subjects: 0
Study 2532136 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 6
Study 2532136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 627044 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tartrazine
Number of subjects: 122
Study 30896192 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital gambling accelerator intervention
Number of subjects: 87
Study 30896192 — intervention group
Group type: COMPARATOR
Intervention: Brief motivational interviewing (MI)
Number of subjects: 87
Study 30896192 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 87
Study 28178298 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400mg)
Number of subjects: 2705
Study 28178298 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40mg/kg)
Number of subjects: 2705
Study 28178298 — intervention group
Group type: COMPARATOR
Intervention: Strongyloidiasis (observational analysis)
Number of subjects: 2705
Study 25007736 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system
Number of subjects: 32
Study 25007736 — intervention group
Group type: COMPARATOR
Intervention: No navigation system
Number of subjects: 32
Study 23728830 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 132
Study 23728830 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 132